Home/Pipeline/MTX325

MTX325

Parkinson's Disease

Phase 1bActive

Key Facts

Indication

Parkinson's Disease

Phase

Phase 1b

Status

Active

Company

Mission Therapeutics

About Mission Therapeutics

Mission Therapeutics is a world leader in deubiquitylating enzyme (DUB) drug discovery and development, leveraging a proprietary platform to identify selective DUB inhibitors. Its lead programs, MTX325 and MTX652, target USP30 to enhance mitophagy and are in clinical development for Parkinson's disease and other conditions. The company is privately held, has raised significant capital and non-dilutive funding, and advances its pipeline through in-house development and strategic partnerships.

View full company profile

Therapeutic Areas

Parkinson's Disease Neurodegenerative Diseases Heart Disease Kidney Disease Fibrosis Mitochondrial Diseases

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active